What is new in chronic lymphocytic leukemia (CLL)? (Episode 3)
0 Views
administrator
07/08/23
The FLAIR trial design is to assess the effectiveness of continuous combination (ibrutinib plus rituximab) as first line treatment or CLL, compared to the current standard of fludarabine, cyclophosphamide and rituximab.
As we are waiting for final long-term results of this trial, Dr. Ahmed Magdy made a short recap about the current evidence and the initial 2-year outcomes of the study.
-
Category
Show more
Facebook Comments
![Erections After Prostate Cancer Treatment with Robert Valenzuela, MD [Episode 45]](https://i.ytimg.com/vi/eerLyyQeibs/maxresdefault.jpg)
No comments found